| Identification | |
| Name: | Propanedinitrile,2-[2-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazinylidene]- |
| Synonyms: | Propanedinitrile,[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]- (9CI);((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile;2-[[4-(4-Methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile; |
| CAS: | 131741-08-7 |
| Molecular Formula: | C14H12N6O |
| Molecular Weight: | 280.28 |
| InChI: | InChI=1/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m0/s1 |
| Molecular Structure: | ![(C14H12N6O) Propanedinitrile,[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]- (9CI);((4-(...](https://img1.guidechem.com/chem/e/dict/180/131741-08-7.jpg) |
| Properties | |
| Density: | 1.336g/cm3 |
| Refractive index: | 1.673 |
| Specification: |
The chemical synonyms of 2-[[4-(4-Methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile (131741-08-7) are 2-[[4-(4-Methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile ; ((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile ; Simendan ; Simendan R--[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl] hydrozono]-propanedinitrile ; R-(-)-4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl hydrozono-propanedinitrile .The product of 2-[[4-(4-Methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile (131741-08-7) has well tolerated, with other cardiovascular drugs such as β blockers, ACE inhibitors, calcium antagonists, nitrates, digoxin, warfarin, aspirin, etc. in conjunction with, the more secure . Abroad have been carried out in several large clinical trials, adverse reactions are mild and rarely serious arrhythmia. |
| Safety Data | |
 |
|
